Internal Medicine Doctors in Lafayette, IN Accepting Medicare

147 Internal Medicine doctors found. Showing 141 - 147

Dr. Ayodeji Oduola, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2600 Ferry St, Lafayette, IN 47904 Phone: 765-448-8000    Fax: 765-838-4698

Dr. Muhammad R. Toor, M.D., DABIM Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1701 S Creasy Ln, Lafayette, IN 47905 Phone: 765-502-4380

Michael W Skehan, MD Internal Medicine - Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 2600 Ferry St, Lafayette, IN 47904 Phone: 765-448-8000    Fax: 765-448-8666

Falguniben Arvindbhai Patel, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2600 Ferry St, Lafayette, IN 47904 Phone: 765-448-8000    Fax: 765-838-4698

Dr. Belinda Kristin Haerum, MD, MPH Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5165 Mccarty Ln, Lafayette, IN 47905 Phone: 765-448-8000    Fax: 765-448-7631

Dr. Rita A. Mankus, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1701 S Creasy Ln, Lafayette, IN 47905 Phone: 765-502-4000    Fax: 765-502-4709

Ying-kei Hui, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5177 Mccarty Ln, Lafayette, IN 47905 Phone: 765-448-8000    Fax: 765-448-7616

News Archive

Study explores link between genetic predisposition to Alzheimer's and cardiometabolic risk factors

Alzheimer's disease is the most common memory disorder. In addition to genetic predisposition, the risk of Alzheimer's disease is also increased by cardiometabolic risk factors, such as type 2 diabetes. The accumulation of these risk factors is known as the metabolic syndrome.

Scientists discover major breakthrough in cancer treatment

Scientists at the Sahlgrenska Academy, University of Gothenburg, have developed a new cancer treatment that has proved to be effective in mice. The treatment, which is presented in the prestigious scientific journal PNAS, is based on newly discovered properties of the so-called BET bromodomain inhibitors.

New CWRU study identifies three glycosyltransferases as major mutational targets in colorectal cancer

Little is known about the molecular basis of aberrant protein glycosylation, a complex enzymatic process that is a hallmark of many human cancers including colorectal cancers (CRC), and how it may contribute to tumor progression. In a new study published in Scientific Reports, an online journal of the Nature Publishing Group, scientists at Case Western Reserve University School of Medicine have successfully characterized the mutational landscapes of glycosylation-associated genes in colon cancer, identifying three glycosyltransferases as significant mutational targets in CRC.

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year.

Read more Medical News

› Verified 2 days ago

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8(current)